Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.

Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L.

Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6.

2.

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Feldman EJ.

Curr Hematol Malig Rep. 2006 Mar;1(1):20-4. doi: 10.1007/s11899-006-0013-8. Review.

PMID:
20425327
3.

Evolution of high-dose cisplatin.

Holleran WM, DeGregorio MW.

Invest New Drugs. 1988 Jun;6(2):135-42. Review.

PMID:
3049431
4.

Cisplatin overdose: toxicities and management.

Tsang RY, Al-Fayea T, Au HJ.

Drug Saf. 2009;32(12):1109-22. doi: 10.2165/11316640-000000000-00000. Review.

PMID:
19916578

Supplemental Content

Support Center